anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: for correction of endothelial dysfunction in experiment on rats dysfunction is modelled by preliminary sensitisation of animal with staphylococcus anatoxin in doze 0.1 ml subcutaneously. Then after 24 hours in the same place as anatoxin introduced is suspension of Staphylococcus aureus subcutaneously in dose 60 billions of microbial bodies in 1 ml. After that for following generalisation of infectious agent, daily massage of injection place is carried out. At this background introduced is macrolidal medication azithromycin intragastrically in dose 30 mg/kg/day. ^ EFFECT: method ensures activation of endothelial dysfunction correction. ^ 1 ex, 1 tbl
PURPOSE: To enable detecting an analyte by causing the analyte to react with a specific coupling partner having biological affinity after a device comes into contact with a fluid, and detecting the analyte using a labeling reagent. CONSTITUTION: A reaction component is located between a moving-phase- adapted zone(MPAZ) and an adsorption zone(AZ), and in a zone in contact with the AZ, it is secured to a solid-phase zone(SPZ) by a covalent bond or by adsorption or via interaction having biological affinity. Coupling is achieved by a reaction that occurs in a device through further reaction components that are secured to the SPZ by a covalent bond or by adsorption or via interaction having biological affinity. Next, a further labeled reaction component (zygote) is located in an uncoupled state between the MPAZ and the SPZ. An analyte-adapted zone is either the MPAZ or a zone between the MPAZ and the AZ. Therefore, the analyte having a biological affinity characteristic can be detected.
FIELD: medicine; obstetrics; hematology.SUBSTANCE: prescribing an anticoagulant preparation or a fibrinolysis inhibitor for women performing an IVF procedure. All women undergoing VRT cycle 3–4 days before embryo transfer (in case of the frozen embryos transfer protocol) or 2–3 days after the oocyte puncture (if the superovulation stimulation protocol is being performed), the haemostasis plasma link is examined by thrombodynamics, estimation of D-dimer level, time of XIIa-dependent fibrinolysis. If observing a pathological increase in the clot formation (and/or initial) rate, as well as a high density of the clot and/or spontaneous clots and if spontaneous clots are detected during 30 minutes of observation, Thrombodynamics (TD) test involves therapy with low-molecular heparins (LMWH) in a preventive dose [Application of thrombodynamics test for evaluation of haemostasis system state: educational-methodical recommendations. Ed. Shulutko A.M. Moscow. 2015]. Further, the state of plasma haemostasis is monitored by TD, D-dimer and XIIa-dependent fibrinolysis at 2, 8, 8–9 days after embryo transfer. If observing an increase in the stationary speed of more than 35 mcm/min or initial velocity of more than 60 mcm/min and/or presence of spontaneous clots within 30 minutes of observation, a preventive dose of low-molecular heparin is adjusted upwards. In case of low clot density by thrombodynamics (less than 25000 opt units), in the absence of increase in the rate of the stationary and/or initial speed above the reference values, the time XIIa-dependent fibrinolysis is evaluated. If patient is 5 minutes or less, the patient is prescribed an orally inhibitory fibrinolysis agent, for period of 3 days or more for the purpose of moderate suppression of hyperfibrinolysis under the control of the same laboratory tests. In case of complaints of idiopathic headache, or elongation of XIIa-dependent fibrinolysis more than 12 min, or increasing the stationary and/or initial rate of clot formation above the reference values, the fibrinolysis inhibitor is canceled and low-molecular heparin is administered in a preventive dose if observing pathological hypercoagulation according to control laboratory tests. Thereafter, the values are monitored every 4 weeks, followed by correcting the dose of low-molecular heparin if necessary.EFFECT: method allows to increase the pregnancy rate after the IVF protocol and ensure successful gestation, adequate correction of hemostasis disorders ensured by individual laboratory monitoring, simplified decision making on the strategy of prescribing preparations (anticoagulants or antifibrinolytics) using the results of three tests assessing the state of the hemostasis system.1 cl, 2 ex
The invention relates generally to the field of immunology. More specifically, the invention relates the finding that antibodies can generate superoxide and hydrogen peroxide from singlet oxygen. Accordingly, methods and compositions able to increase or decrease oxidative stress are provided. Also provided are screening assays to identify agents that modulate the ability of a antibody to generate superoxide and hydrogen peroxide. Such agents can be used therapeutically to treat patients in need. Further, the invention provides methods to use antibodies in immunoassays.
The invention discloses a preparation method of nitrogen-containing mustard-based flavonoid derivatives and application of the nitrogen-containing mustard-based flavonoid derivatives in antitumor activity research. Is shown in formula I and formula II, wherein n is 1,2 and 3. The target compound is not reported in the literature. The compounds can inhibit the growth activity of various tumor cells. Experiments show that the target compound shows better anti-tumor activity on 7 tested cancer cells, and compared with the existing anti-tumor drug 5-fluorouracil, the growth inhibition activity of the target compound on various tumor cells is obviously higher than that of the target compound; wherein the target compound II 2 The antitumor effect was best, and IC was found to be in Hela, DU145, PC-3, MCF-7, SH-SY5Y cells 50 The values are all below 10 mu M and are all in the same order of magnitude compared with the antineoplastic drug cisplatin. Further research shows that the target compound II 2 Apoptosis can be induced in G2/M phase by cell cycle arrest with He L a, compound of interest II 2 Is expected to become a novel anti-tumor medicament.
The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is now acknowledged as a significant public health concern, a persistent neurodevelopmental disorder. It poses challenges across various life domains, persisting into adulthood, and is often undiagnosed. From July 2023 to December 2023, this study investigated the prevalence, types, participants' knowledge and perceptions, and demographic determinants of undiagnosed adult ADHD among undergraduate medical students in Pakistan.
METHODS: This cross-sectional study enrolled 342 undergraduate medical students who fulfilled the selection criteria. The data was collected using an online self-administered survey consisting of three main parts using the WHO 18-question Adult ADHD Self-Report Scale, Version 1.1 (ASRS-v1.1), to assess adult ADHD symptoms. Data analysis was conducted using SPSS (version 26.0).
RESULTS: 119 medical students, or 34.8%, had adult ADHD. Inattentive dominance was the most prevalent presentation at (86, 72.3%), followed by mixed dominance at (20, 16.8%), and hyperactive dominance at (13, 10.9%). There was a statistically significant (p < 0.05) association between individuals who screened positive for adult ADHD and had co-occurring psychological disorders (e.g., anxiety, depression) and a family history of psychiatric disorders (e.g., ADHD, generalized anxiety disorder, bipolar disorder). Additionally, these individuals perceived that individuals with adult ADHD could live a normal life despite their condition. While the type of ADHD was significantly associated with the use of medications for psychological disorders, it was significantly higher among hyperactive dominants (5,71.4%), and the family history of GAD was significantly higher (2,10.0%) among mixed dominants.
CONCLUSION: This study reveals a significant prevalence of undiagnosed adult ADHD and an inattentive dominance among medical students in Pakistan, highlighting gaps in awareness and screening. These findings emphasize the crucial need for implementing ADHD screening programs.
A pituitous silicone fluid includes a hydrosilylation reaction product and a carrier fluid. The hydrosilylation reaction product is the reaction product of a first linear organopolysiloxane and a second linear organopolysiloxane. The first linear organopolysiloxane includes (R1R2R3SiO1/2) and (R4R5SiO2/2) units. Each of R1-R5 is independently a hydrocarbon group so long as at least one of R1-R5 is an alkenyl group. In addition, the first linear organopolysiloxane has a degree of polymerization of from 100 to 15,000. The second linear organopolysiloxane includes (R6R7R8SiO1/2) and (R9R10SiO2/2) units. Each of R6-R10 is independently a hydrocarbon group, polyether group, siloxane group, or polyol group, so long as at least one of R6-R10 is a hydrogen atom. In addition, the second linear organopolysiloxane has a degree of polymerization of from 4 to 1,000. The hydrosilylation reaction product includes alkenyl or Si—H functionality. Personal care compositions can include the pituitous silicone fluid.
A portable PEMF device will be utilized. For the PEMF group, the device includes adjustable magnetic field strength range (X-axis: 0.22±0.05 mT, Y-axis: 0.20±0.05 mT and Z-axis: 0.06±0.02 mT) and working frequency (30±3Hz). This magnetic strength range and frequency will be maintained during 180 days of the study period. The subjects will be instructed to use their device three times per day: providing micromagnetic emitting on both hands (palms) during morning, afternoon and evening/night sessions. Each session takes 16 min (both hands, 8 min per hand) and thus subjects are exposed to therapy for 48 min per day. Subjects will use the device as outlined continuously up through the final days of testing.
The cellular stress response system in immune cells plays a crucial role in regulating the development of inflammatory diseases. In response to cellular damage or microbial infection, the assembly of the NLRP3 inflammasome induces pyroptosis and the release of inflammatory cytokines. Meanwhile, Angiogenin (Ang)-mediated transfer RNA-derived small RNAs (tsRNAs) promote cell survival under stressful conditions. While both tsRNAs and inflammasomes are induced under stress conditions, the interplay between these two systems and their implications in regulating inflammatory diseases remains poorly understood. In this study, it was demonstrated that Ang deficiency exacerbated sodium arsenite-induced activation of NLRP3 inflammasome and pyroptosis. Moreover, Ang-induced 5'-tsRNAs inhibited NLRP3 inflammasome activation and pyroptosis. Mechanistically, 5'-tsRNAs recruit DDX3X protein into stress granules (SGs), consequently inhibiting the interaction between DDX3X and NLRP3, thus leading to the suppression of NLRP3 inflammasome activation. Furthermore, in vivo results showed that Ang deficiency led to the downregulation of tsRNAs, ultimately leading to an exacerbation of NLRP3 inflammasome-dependent inflammation, including lipopolysaccharide-induced systemic inflammation and type-2 diabetes-related inflammation. Altogether, our study sheds a new light on the role of Ang-induced 5'-tsRNAs in regulating NLRP3 inflammasome activation via SGs, and highlights tsRNAs as a promising target for the treatment of NLRP3 inflammasome-related diseases.
A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
PURPOSE:To obtain the subject assistant liquid, containing a film-forming component capable of forming a film having releasability from a nail or the skin and adhesion to a nail enamel and capable of removing the nail enamel without using an enamel remover. CONSTITUTION:An assistant liquid containing 5-40wt.% film-forming ingredient capable of forming a film having releasability from a nail or skin and adhesion to a nail enamel, e.g. PVA, vinyl acetate resin emulsion, CMC or polyvinylpyrrolidone. The aforementioned liquid is applied to the surface of the nail to form a film having releasability and a nail enamel is then applied thereon. The formed releasable film can be peeled to remove the nail enamel. The above-mentioned liquid is applied to the skin around the nail to form a releasable film and the nail enamel can be then applied to readily remove parts protruding from the nail together with the releasable film. Thereby, the nail can be beautifully manicured.
PURPOSE:To obtain an antibody complex without decreasing antigen-binding activity, by modifying with a reversible modifying agent part of amino groups of antibodies which antigen-binding activity is reduced by modification of amino groups, reacting with a substance containing a functional group reactive with amino group and removing the residue of the modifying agent. CONSTITUTION:Part of amino groups of an antibody or fragment thereof, which antigen-biding activity is reduced by modification of amino groups, is modified with a reversible modifying agent for a protein-amino group (e.g. dimethyl-maleic anhydride) and the antibody or fragment thereof is reacted with a substance having an amino-reactive functional group (e.g. methotorexate N- hydroxysuccinimide ester). Then the residues of the reversible modifying agent on protein amino groups are removed from the reaction product. When residues of the substance having an amino-reactive functional group is introduced into functional group other than amino group, those residues are eliminated as necessary, to afford the aimed antibody complex.
Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
Reperfusion injury, which is distinct from ischaemic injury, occurs when blood flow is restored in previously ischaemic brain tissue, further compromising neurons and other cells and worsening the injury. There is currently a lack of pharmaceutical agents and therapeutic interventions that specifically mitigate cerebral ischaemia/reperfusion (I/R) injury. Ginsenoside Rg1 (Rg1), a protopanaxatriol-type saponin isolated from Panax ginseng C. A. Meyer, has been found to protect against cerebral I/R injury, but its intricate protective mechanisms remain to be elucidated. Numerous studies have shown that autophagy plays a crucial role in protecting brain tissue during the I/R process and is emerging as a promising therapeutic strategy for effective treatment. In this study, we investigated whether Rg1 protected against I/R damage in vitro and in vivo by regulating autophagy. Both MCAO and OGD/R models were established. SK-N-AS and SH-SY5Y cells were subjected to OGD followed by reperfusion with Rg1 (4-32 μM). MCAO mice were injected with Rg1 (30 mg·kg-1·d-1. i.p.) for 3 days before and on the day of surgery. Rg1 treatment significantly mitigated ischaemia/reperfusion injury both in vitro and in vivo. Furthermore, we demonstrated that the induction of autophagy contributed to I/R injury, which was effectively inhibited by Rg1 in both in vitro and in vivo models of cerebral I/R injury. Rg1 inhibited autophagy through multiple steps, including impeding autophagy initiation, inducing lysosomal dysfunction and inhibiting cathepsin enzyme activities. We revealed that mTOR activation was pivotal in mediating the inhibitory effect of Rg1 on autophagy. Treatment with Torin-1, an autophagy inducer and mTOR-specific inhibitor, significantly reversed the impact of Rg1 on autophagy, decreasing its protective efficacy against I/R injury both in vitro and in vivo. In conclusion, our results suggest that Rg1 may serve as a promising drug candidate against cerebral I/R injury by inhibiting autophagy through activation of mTOR signalling.
The COVID-19 pandemic altered daily family routines, with the family food environment especially likely to be affected. Little is known about how families have adapted over time. The objective of the current study was to explore how family food habits evolved three years after COVID-19 was designated a pandemic. Mothers participated in an interview between March and April 2023. Reflexive thematic analysis was used to analyze the transcripts. Thirty mothers participated (97% lived in the Central Valley in California; 43% Hispanic). Themes were identified around changes in mealtime frequency, eating habits including snacking, screen time during mealtimes, and weight gain. While some unhealthy habits established during the pandemic improved, others persisted three years later. Maternal snacking, concerns about child weight gain, and overall screen time lessened after the pandemic ended, but child snacking behaviors, maternal weight gain concerns, and screen time during mealtimes continued. This research expands on the existing COVID-19 literature by examining lingering effects of the pandemic on family food habits. Findings may be helpful for health practitioners working with families to understand food related changes post-pandemic, especially those that have been particularly resistant to change.
PROBLEM TO BE SOLVED: To obtain the subject preparation for external use, having unnaturally white coating color when using, capable of manifesting excellent activities for protecting ultraviolet rays by combining a specific fine particles of titanium dioxide with a specific ultraviolet absorber and/or an ultraviolet-scattering agent. SOLUTION: This preparation for external use is obtained by formulating (A) fine particles of titanium dioxide preferably having average primary particle diameter of 10-100 nm, and substantially in the state of non-cohesion and (B) an absorbing agent of ultraviolet rays A (preferably 4-tert-butyl-4'- methoxybenzoylmethane, etc.), and/or a scattering agent of ultraviolet rays A. The scattering agent of the ultraviolet rays A is preferably a powder of zinc oxide, cerium oxide or the like and preferably has an average particle diameter of 10-150 nm. Preferably, the component A is formulated in the proportion of 1-25 wt.% in the preparation for external use. The component B is preferably formulated in the proportion of 1-25 wt.% when the scattering agent of the ultraviolet rays A is used.  When the absorbing agent of the ultraviolet rays A is used, the component B is preferably formulated in the proportion of 0.5-10%.
Chronic use of omeprazole has been linked to central effects alongside with the global concern of increasing appearance of neuropsychiatric disorders. This study aimed to identifying behavioral, inflammatory, and oxidative stress alterations after long-term administration of omeprazole. C57BL/6 mice were divided in groups: OME and Sham, each received either solutions of omeprazole or vehicle, administered for 28 days by gavage. Results observed in the omeprazole-treated mice: Decrease in the crossing parameter in the open field, no change in the motor performance assessed by rotarod, an immobility time reduction in the forced swimming test, improved percentage of correct alternances in the Ymaze and an exploration time of the novel object reduction in the novel object recognition. Furthermore, a reduced weight gain and hippocampal weight were observed. There was an increase in the cytokine IL1-β levels in both prefrontal cortex (PFC) and serum, whereas TNF-α increased only in the PFC. Nitrite levels increased in the hippocampus (HP) and PFC, while malondialdehyde (MDA) and glutathione (GSH) levels decreased. These findings suggest that omeprazole improves depressive-like behavior and working memory, likely through the increase in nitrite and reduction in MDA levels in PFC and HP, whereas, the impairment of the recognition memory is more likely to be related to the reduced hippocampal weight. The diminished weight gain might be associated with the IL-1β increased levels in the peripheral blood. Altogether, omeprazole showed to have the potential to impact at central level and inflammatory and oxidative parameters might exert a role between it.
PURPOSE:To obtain a urokinase useful as a remedy for thrombosis and cardial infarction, in high yield and purity, by adsorbing urokinase to a water-insoluble carrier having a specific group as a ligand, and eluting the adsorbed urokinase with a specific amino compound. CONSTITUTION:Crude urokinase is adsorbed to a water-insoluble carrier having the group of formula (X is OH, CH3, phenyl, etc.; n is integer of 3-10) (e.g. agarose, cellulose, etc.), and the adsorbed urokinase is eluted and purified with a compound having >=2-valent amino group (e.g. diaminomonocarboxylic acid such as lysine, arginine, etc.) or its salt. The insoluble carrier having the group of formula is e.g. Butyltoyopearl (product of Toyo Soda Ind. Co.), etc. The carrier and elutant used in the present adsorption process has improved selectivity to adsorb and elute urokinase, and accordingly, the process is substantially advantageous as the industrial process for the production of urokinase.
PURPOSE: A method for treating or preventing circovirus infection in an animal using a novel circovirus type 2(PCV2) is provided to ensure high replication ability in a host cell and efficiency. CONSTITUTION: A composition for preventing or treating circovirus infection in an animal contains inactivated circovirus PCV2 GC0504 or PCV2 GC0505 inactivated virus. The PCV2 GC0504 has a genome sequence with a nucleotide of sequence number 1. The PCV2 GC0505 has a genome sequence with a nucleotide of sequence number 4. The inactivation is performed by reacting PCV2 GC0504 and PCV2 GC0505 with formaldehyde. The composition further contains 5-15% of veterinary acceptable excipient, montanide gel.
PURPOSE: To obtain the subject composition containing a pronase and an antimicrobial agent as active ingredients, capable of surely and safely eradicating Helicobacter pylori in a short period in a high probability and useful for the prevention and therapy of peptic ulcer, etc., caused by the infection of the bacteria and for the prevention of their recurrences. CONSTITUTION: This eradicating composition for Helicobacter pylori contains a pronase and an antimicrobial agent as active ingredients. As the antimicrobial agent, a combined use of three kinds of antimicrobial agents such as bismuth subnitrate as a bismuth preparation, amoxicillin as an antibiotic agent and metronidazole as an antiprotozoal agent, is preferable. Also, the objective composition is preferably a liquid preparation. In the case that the objective composition is the liquid preparation, the blending amount of 0.2-0.4wt.% pronase and the total blending amount of 3-10wt.% antimicrobial agents are preferable.  Further, in order to conduct the eradicating treatment, it is preferable to dam up the angulus of an upper duodenum to prevent the flow out of a gastric content, then to inject the above composition directly into the stomach, to expose whole gastric wall to the composition while changing a patient's posture, and then, further to discharge the gastric content from the stomach after the completion of the treatment.
This cohort includes patients with an impalpable breast lesion that are scheduled for breast conserving surgery with Magseed localisation after September 2018. Their data will be prospectively collected and analysed.